Treatment-resistant psoriasis presents significant challenges due to persistent inflammation and limited responses to conventional therapies. Targeted biologics, particularly IL-17 and IL-23 inhibitors, ... Nov 02
Psoriatic Arthritis (PsA) is a chronic, heterogeneous, systemic inflammatory musculoskeletal disease affecting roughly 20% to 30% of individuals diagnosed with cutaneous psoriasis. PsA belongs to ... Aug 04
Psoriatic Arthritis (PsA) is a chronic, heterogeneous, systemic inflammatory musculoskeletal disease affecting roughly 20% to 30% of individuals diagnosed with cutaneous psoriasis. PsA belongs to ... Aug 01
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in the first-of-its-kind study... Nov 05
EU approval for Novartis secukinumab drug... Aug 05
-Advertisements-